» Articles » PMID: 33520115

Reversing Oncogenic Transformation with Iron Chelation

Overview
Journal Oncotarget
Specialty Oncology
Date 2021 Feb 1
PMID 33520115
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer cells accumulate iron to supplement their aberrant growth and metabolism. Depleting cells of iron by iron chelators has been shown to be selectively cytotoxic to cancer cells and . Iron chelators are effective at combating a range of cancers including those which are difficult to treat such as androgen insensitive prostate cancer and cancer stem cells. This review will evaluate the impact of iron chelation on cancer cell survival and the underlying mechanisms of action. A plethora of studies have shown iron chelators can reverse some of the major hallmarks and enabling characteristics of cancer. Iron chelators inhibit signalling pathways that drive proliferation, migration and metastasis as well as return tumour suppressive signalling. In addition to this, iron chelators stimulate apoptotic and ER stress signalling pathways inducing cell death even in cells lacking a functional p53 gene. Iron chelators can sensitise cancer cells to PARP inhibitors through mimicking BRCAness; a feature of cancers trademark genomic instability. Iron chelators target cancer cell metabolism, attenuating oxidative phosphorylation and glycolysis. Moreover, iron chelators may reverse the major characteristics of oncogenic transformation. Iron chelation therefore represent a promising selective mode of cancer therapy.

Citing Articles

Bafilomycin A1 induces colon cancer cell death through impairment of the endolysosome system dependent on iron.

Min D, Kim D, Hong S, Kim J, Kim M, Kwon S Sci Rep. 2025; 15(1):5148.

PMID: 39934167 PMC: 11814099. DOI: 10.1038/s41598-025-89127-5.


Deferasirox's Anti-Chemoresistance and Anti-Metastatic Effect on Non-Small Cell Lung Carcinoma.

Delgado Y, Torres-Sanchez A, Perez D, Torres G, Estrada S, Ortiz Alvelo N Biomedicines. 2024; 12(10).

PMID: 39457585 PMC: 11505511. DOI: 10.3390/biomedicines12102272.


In Vitro Glioblastoma Model on a Plate for Localized Drug Release Study from a 3D-Printed Drug-Eluted Hydrogel Mesh.

Chehri B, Liu K, Vaseghi G, Seyfoori A, Akbari M Cells. 2024; 13(4.

PMID: 38391976 PMC: 10887613. DOI: 10.3390/cells13040363.


Assessing the Potential of Small Peptides for Altering Expression Levels of the Iron-Regulatory Genes and and Enhancing Androgen Receptor Inhibitor Activity in In Vitro Prostate Cancer Models.

Currie C, Bjerknes C, Myklebust T, Framroze B Int J Mol Sci. 2023; 24(20).

PMID: 37894914 PMC: 10607736. DOI: 10.3390/ijms242015231.


Chelators as Antineuroblastomas Agents.

DAcunto C, Gbelcova H, Kaplanek R, Pospisilova M, Havlik M, Ruml T Physiol Res. 2023; 72(S3):S277-S286.

PMID: 37888971 PMC: 10669945. DOI: 10.33549/physiolres.935184.


References
1.
Gray M, Zhang J, Ellis L, Semenza G, Evans D, Watowich S . HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene. 2005; 24(19):3110-20. DOI: 10.1038/sj.onc.1208513. View

2.
Helson L . In vivo effects of repeated exposure of human neuroblastoma cell lines to deferoxamine. Anticancer Res. 1991; 11(1):409-10. View

3.
Kuang Y, Guo W, Ling J, Xu D, Liao Y, Zhao H . Iron-dependent CDK1 activity promotes lung carcinogenesis via activation of the GP130/STAT3 signaling pathway. Cell Death Dis. 2019; 10(4):297. PMC: 6443808. DOI: 10.1038/s41419-019-1528-y. View

4.
Leanderson P, Tagesson C . Iron bound to the lipophilic iron chelator, 8-hydroxyquinoline, causes DNA strand breakage in cultured lung cells. Carcinogenesis. 1996; 17(3):545-50. DOI: 10.1093/carcin/17.3.545. View

5.
Kovacevic Z, Fu D, Richardson D . The iron-regulated metastasis suppressor, Ndrg-1: identification of novel molecular targets. Biochim Biophys Acta. 2008; 1783(10):1981-92. DOI: 10.1016/j.bbamcr.2008.05.016. View